Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations.  The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2010 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Neurologix Completes Additional $7 Million Financing
    5. Neurologix Announces First Quarter 2011 Financial Results
    6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
    8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
    11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2015)... , May 22, 2015 /CNW/ - More than fifty years ... treat morning sickness in expectant mothers. Tragically, Thalidomide caused serious ... families. Support has been provided to survivors ... of Canada in 1991 and settlements ... of a legal obligation to provide support, we have a ...
    (Date:5/22/2015)... ORLANDO, Fla. , May 22, 2015 ... Copay Assistance Program. This program provides financial assistance for ... "We are pleased to announce the addition of the ... programs," stated Mark McGreevy , executive director. "With ... mission and vision of a world where no one ...
    (Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
    Breaking Medicine Technology:Statement from Minister Ambrose on Thalidomide 2Statement from Minister Ambrose on Thalidomide 3The Assistance Fund Adds Melanoma Assistance Program 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3
    ... ANN ARBOR, Mich., Sept. 27 The National ... Therapeutics, Inc. as,an award winner in the Commerce ... announced today that $2 million,was awarded to the ... osteoporosis, bone cancer, bone fractures, and,other bone disorders. ...
    ... Require Further Investigations," Says ... Dissenting Panel Member, ... (CDC),study on the relationship between mercury (thimerosal) in vaccines and,children,s ... external consultants, Sallie Bernard, Executive Director of,SafeMinds. "Early Thimerosal ...
    Cached Medicine Technology:NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease 2Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds 2
    (Date:5/24/2015)... 24, 2015 Women's Excellence in ... loss. Although it is unclear about the etiology of ... factors such as metabolism, nutritional deficiencies, thyroid abnormalities and ... a comprehensive approach to evaluating the metabolic, nutritional and ... can help patients find a cause for their problem. ...
    (Date:5/24/2015)... 24, 2015 EnviroLeather™ by LDI, ... Plus” – a classic, rugged leather grain with ... difficult stains, including ink, to be easily removed. ... suitable for corporate, healthcare, hospitality and education environments. ... EnviroLeather’s goal of developing products that are more ...
    (Date:5/24/2015)... (PRWEB) May 24, 2015 Medicx ... Millennial Media strategy executive Jay Krihak as its ... looks to ramp up its expertise and leadership ... the Pharmaceutical and Health sectors. , Krihak is ... executive. Most recently, Krihak led sales planning teams ...
    (Date:5/23/2015)... (PRWEB) May 23, 2015 On May ... powers of a youngster's yogic power learned through meditation ... Nithyananda Swami in Bangalore, India. , Yogamaatha, a nine-year-old ... than 50 high profile professionals attending the 2015 Business ... reading fluently -- blindfolded. , In a demonstration ...
    (Date:5/23/2015)... 2015 On May 16, the team at ... was a 5k mud obstacle run that raised funds for ... people worldwide, and the reason we participated was to support ... owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent of the funds ... The event was not only attended by eXtreme Bodyshaping staff, ...
    Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
    ... (HealthDay News) -- People with heart disease who undergo cardiac ... normal rate after exercise, a new study suggests. Researchers ... rate recovery live longer than those whose hearts remain revved ... medicine that can do that," study author Dr. Leslie Cho, ...
    ... , MONDAY, Sept. 26 (HealthDay News) -- ... few weeks achieve quicker control of their blood glucose, ... Control of these levels reduces the risk of diabetes-related ... levels under control. Current treatment guidelines do not outline ...
    ... HealthDay Reporter , MONDAY, Sept. 26 (HealthDay News) -- Too ... and more problems with thinking skills as people age, new ... from B-12 deficiencies may be greater than thought because current ... accurate, said Christine C. Tangney, lead author of the study ...
    ... other medical professionals occasionally joke about their patients, problems. ... joking between medical professionals is not only ethical, it ... Hastings Center Report . The author, Katie ... she is an assistant professor in the Medical Humanities ...
    ... 145,000 deaths could be averted in the next 30 ... policies. This set of policies, as recommended by the ... increasing tobacco taxes to 70% of the retail price, ... complete marketing ban, well-funded tobacco control campaigns, graphic health ...
    ... YORK, N.Y. (September 26, 2011) The Autism Speaks ... federal grant to continue to serve as the Autism ... supports clinical research, development of best-practice guidelines, tool kits ... "This agreement provides the ATN with a jump start ...
    Cached Medicine News:Health News:Cardiac Rehab May Help Heart Patients Live Longer 2Health News:More Frequent Doctor Visits May Benefit Diabetes Patients 2Health News:Could Too Little Vitamin B-12 Shrink the Aging Brain? 2Health News:Could Too Little Vitamin B-12 Shrink the Aging Brain? 3Health News:Is gallows humor in medicine wrong? 2Health News:Stronger tobacco control policy in the Netherlands would save thousands of lives 2Health News:Autism Speaks Autism Treatment Network receives $12 million AIR-P grant 2
    The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
    ... lightweight and balanced for smooth, one-handed control. ... comfort, reducing fatigue in even the longest ... physician to easily steer the catheter through ... one finger. Reflexion's auto-lock technology keeps the ...
    The True Non-Compliant Balloon....
    ... Jude Medical's universal programmer platform, the ... in combination with St. Jude Medical® ... for emerging indications. Features a ... active matrix LCD screen Programmer offers ...
    Medicine Products: